175204-88-3

Basic information

• Product Name: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;ETHYL 2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOLE-4-CARBOXYLATE;ETHYL 2-[4-(TRIFLUOROMETHYL)PHENYL]THIAZOLE-4-CARBOXYLATE;Ethyl 2-[4-(trifluoromethyl)phenyl]thiazole-4-carboxylate 97%;Ethyl2-[4-(trifluoromethyl)phenyl]thiazole-4-carboxylate97%;4-Thiazolecarboxylic acid, 2-[4-(trifluoromethyl)phenyl]-, ethyl ester;methyl 2-(4-(trifluoromethyl)phenyl)thiazole-4-carboxylate
• CAS NO: 175204-88-3
• Molecular Formula: C₁₃H₁₀F₃NO₂S
• Molecular Weight: 301.28
• Mol File: 175204-88-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 103-106°C
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(175204-88-3)
• EPA Substance Registry System: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(175204-88-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-22
• Safety Statements: 26-36/37/39-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 175204-88-3(Hazardous Substances Data)

Usage

General Description

2-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester is a chemical compound with the molecular formula C13H10F3NO2S and a molecular weight of 315.29 g/mol. It is a thiazole derivative with a trifluoromethyl-substituted phenyl group and an ethyl ester functional group. 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER has potential applications in pharmaceuticals and agrochemicals, as thiazole derivatives have been studied for their anti-inflammatory, antibacterial, and antifungal properties. The trifluoromethyl group can enhance the biological activity and metabolic stability of the compound, making it potentially valuable for drug development. However, further research is needed to fully understand its potential applications and safety considerations.

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 1221437-20-2 C₁₃H₁₂F₃NO₂S 
• 1332708-70-9 C₁₃H₁₂F₃NO₂S 
• 87427-94-9 (4-Trifluoromethyl-benzoylamino)-acetic acid ethyl ester 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 868-59-7 L-cysteine ethyl ester hydrochloride 
• 41731-52-6 2-chloro-thiazole-4-carboxylic acid ethyl ester 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 

Downstream Products

• 1373143-63-5 N-{5-methyl-6-[4-(morpholin-4-yl)cyclohex-1-en-1-yl]pyridin-3-yl}-2-[4-(trifluoromethyl)-phenyl]thiazole-4-carboxamide 
• 288161-17-1 2-[4-(trifluoromethyl)phenyl]thiazole-4-carbohydrazide 
• 144061-16-5 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxylic acid 
• 857284-25-4 {2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl}methanol 

Relevant articles and documents

INHIBITORS OF HUMAN ATGL

The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Powerful Antibacterial Activity of Phenyl-Thiolatobismuth(III) Complexes Derived from Oxadiazolethiones

Seven novel 5-substituted phenylthiazole oxadiazolethiones: [Me-PTOT(H)], [MeO-PTOT(H)], [MeS-PTOT(H)], [F-PTOT(H)], [Cl-PTOT(H)], [Br-PTOT(H)], and [CF3-PTOT(H)], {where X-PTOT(H) = 5-[2-(4-X)thiazol-4-yl]-1,3,4-oxadiazole-2(3H)-thione, 4-X = C6H4}, were synthesised from their corresponding thioamides. From these seven heteroleptic thiolatobismuth complexes: BiPh(Me-PTOT)2 6, BiPh(MeO-PTOT)2 7, BiPh(MeS-PTOT)2 8, BiPh(F-PTOT)2 9, BiPh(Cl-PTOT)2 10, BiPh(Br-PTOT)2 11 and BiPh(CF3-PTOT)2 12 were synthesised and characterised. Complexes [10(DMSO)2] and [11(DMSO)2] were structurally characterised using X-ray diffraction. Evaluation of the antibacterial properties of the thiones and their BiIII complexes against Mycobacterium smegmatis, Staphylococcus aureus (S. aureus), Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), Enterococcus faecalis (E. faecalis) and Escherichia coli (E. coli) showed that all bismuth(III) complexes were highly effective against all the bacteria, as demonstrated by very low MIC values (1.1-2.1 μM). Complexes BiPh(Me-PTOT)2 6, BiPh(Cl-PTOT)2 10 and BiPh(Br-PTOT)2 11, showed best activity against the multi-drug resistant bacteria VRE and MRSA with an MIC value of 1.0 μM. All these complexes and their corresponding thiones failed to show any prominent activity against M. smegmatis and E. coli, even at high concentrations. These complexes showed little or no toxicity towards mammalian COS-7 cells at 20 μg/mL. Seven heteroleptic thiolatobismuth(III) complexes [BiPh(X-PTOT)2] derived from a series of 5-substituted phenylthiazole oxadiazolethiones [X-PTOT(H)] provide powerful antibacterial action against the multi-resistant bacteria MRSA and VRE.